Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;97(39):e12336.
doi: 10.1097/MD.0000000000012336.

Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review

Jietao Lin  1 , Yang Cao, Ling Yu, Lizhu Lin
Affiliations
Review

Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review

Jietao Lin et al. Medicine (Baltimore). 2018 Sep.

Abstract

Rationale: Adrenal hepatoid adenocarcinoma typically secretes alpha-fetoprotein (AFP). Here, we report a case of non-AFP-producing adrenal hepatoid adenocarcinoma. Next-generation sequencing (NGS) was conducted to identify gene mutations.

Patient concerns: A 64-year-old man presented with mild back pain and unexplained weight loss for 3 months.

Diagnoses: Contrast-enhanced magnetic resonance imaging (MRI) showed a mass (9.9 × 9.7 × 9.1 mm) above the upper pole of the left kidney. The left renal artery and vein were compressed. The tumor was positive for CK8/18, CK19, CK7, hepatocyte marker (Hepatocyte), and Hep Par 1, but negative for AFP. Plasma AFP was 2.75 ng/mL (normal range: 0-7 ng/mL). NGS revealed mutations of the following genes: ATM, CDKN2A, EGFR, STK11, TP53, BIM, and MLH1. A diagnosis of adrenal hepatoid adenocarcinoma was established.

Interventions: The treatment included 4 cycles of the mFOLFOX6 regimen (oxaliplatin, leucovorin, and fluorouracil), transcatheter arterial chemoembolization, and apatinib.

Outcomes: The patient died 9 months after the diagnosis.

Lessons: This case highlights the importance of thorough clinical, radiological, and immunohistochemical investigation for suspected adrenal hepatoid adenocarcinoma. Metastasis from other primary tumors should be ruled out. Furthermore, AFP is not necessarily elevated in adrenal hepatoid adenocarcinoma. NGS could be helpful in establishing the diagnosis and selecting treatments.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Histologic examination of the suprarenal mass shows atypical cells, arranged in acinar and cord-like patterns, with mucus secretion. H&E staining; magnification: ×100.
Figure 2
Figure 2
18F-FDG imaging of the suprarenal mass. The tumor size is 9.8 × 9.3 × 10.8 cm3. SUV max value is between 2.4 and 7.8, with an average between 2.1 and 6.9.
Figure 3
Figure 3
Immunostaining of the lesion. Left: Hep Par1 (+); right: vimentin (−). Magnification: ×100.
See this image and copyright information in PMC

References

    1. Ishikura H, Fukasawa Y, Ogasawara K, et al. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report. Cancer 1985;56:840–8. - PubMed
    1. Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol 2007;38:857–63. - PubMed
    1. Gakiopoulou H, Givalos N, Liapis G, et al. Hepatoid adenocarcinoma of the gallbladder. Dig Dis Sci 2007;52:3358–62. - PubMed
    1. Liu Q, Bannan M, Melamed J, et al. Two cases of hepatoid adenocarcinoma of the intestine in association with inflammatory bowel disease. Histopathology 2007;51:123–5. - PubMed
    1. Hayashi Y, Takanashi Y, Ohsawa H, et al. Hepatoid adenocarcinoma in the lung. Lung Cancer 2002;38:211–4. - PubMed

MeSH terms

Supplementary concepts